Aion Therapeutic Inc (TSE:AION) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Aion Therapeutic Inc. has acquired the global licensing rights for I2Pure Corp’s patented molecular iodine, aiming to revolutionize water disinfection through Toppen Health’s advanced filtration systems. The new technology will enable the removal of pathogens, PFAS, and pharmaceuticals, promising cleaner water with the help of I2Pure’s slow-release iodine. The deal includes a cash payment and share payments totaling USD $1.25 million.
For further insights into TSE:AION stock, check out TipRanks’ Stock Analysis page.